Natalizumab and central nervous system lymphoma: No clear association
β Scribed by Carmen Bozic; Julia LaGuette; Michael A. Panzara; Alfred W. Sandrock
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 41 KB
- Volume
- 66
- Category
- Article
- ISSN
- 0364-5134
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract A 40βyearβold man with relapsingβremitting multiple sclerosis (MS) developed primary central nervous system lymphoma (PCNSL) after having received 21 doses of natalizumab monotherapy. PCNSL is a disease of the elderly, with the majority of patients being diagnosed in the 7th to 8th deca
BACKGROUND. Primary central nervous system malignant lymphoma (PCNSL) has been regarded as a rare neoplasm. Recently, however, its incidence has been rapidly increasing. Despite active clinical trials, its clinical and biologic features remain unknown and there has been no effective treatment or pro